Citations (119)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Rong Dong, Youyou Yan, Xiaokang Zeng, Nengming Lin & Biqin Tan. (2022) Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Drug Design, Development and Therapy 16, pages 3225-3239.
Read now
Read now
Zhen Zhu, Lanlan Ling, Lezhong Qi, Yue Chong & Li Xue. (2020) Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer. OncoTargets and Therapy 13, pages 4113-4122.
Read now
Read now
Seema A. Bhat & Jennifer A. Woyach. (2020) Changing landscape of frontline therapy in chronic lymphocytic leukemia. Leukemia & Lymphoma 61:3, pages 525-535.
Read now
Read now
T. Seiler & M. Dreyling. (2017) Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives. Expert Opinion on Investigational Drugs 26:8, pages 909-915.
Read now
Read now
David Tucker & Simon Rule. (2017) Novel agents in mantle cell lymphoma. Expert Review of Anticancer Therapy 17:6, pages 491-506.
Read now
Read now
Prithviraj Bose, Varsha V. Gandhi & Michael J. Keating. (2016) Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opinion on Drug Metabolism & Toxicology 12:11, pages 1381-1392.
Read now
Read now
Parviz Kokhaei, Farhad Jadidi-Niaragh, Abdolreza Sotoodeh Jahromi, Anders Osterborg, Håkan Mellstedt & Mohammad Hojjat-Farsangi. (2016) Ibrutinib-A double-edge sword in cancer and autoimmune disorders. Journal of Drug Targeting 24:5, pages 373-385.
Read now
Read now
Gayathri Natarajan, Cesar Terrazas, Steve Oghumu, Sanjay Varikuti, Jason A Dubovsky, John C Byrd & Abhay R Satoskar. (2016) Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. OncoImmunology 5:1.
Read now
Read now
David L Tucker & Simon A Rule. (2015) A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Therapeutics and Clinical Risk Management 11, pages 979-990.
Read now
Read now
Leila Kokabee, Xianhui Wang, Christopher J Sevinsky, Wei Lin Winnie Wang, Lindsay Cheu, Sridar V Chittur, Morteza Karimipoor, Martin Tenniswood & Douglas S Conklin. (2015) Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biology & Therapy 16:11, pages 1604-1615.
Read now
Read now
Nimish Shah, Claire Hutchinson & Simon Rule. (2014) Ibrutinib for the treatment of mantle cell lymphoma. Expert Review of Hematology 7:5, pages 521-531.
Read now
Read now
Ana-Maria Dragoi & Hervé Agaisse. (2014) Tyrosine kinases, drugs, and Shigella flexneri dissemination. Gut Microbes 5:1, pages 44-47.
Read now
Read now
Mohammed ZH Farooqui & Adrian Wiestner. (2013)
Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 1:11, pages 925-933.
Read now
Read now
Jeanette K Doorduijn & Hanneke C Kluin-Nelemans. (2013) Management of mantle cell lymphoma in the elderly patient. Clinical Interventions in Aging 8, pages 1229-1236.
Read now
Read now
Articles from other publishers (105)
Léa N. C. Rochet, Calise Bahou, Jonathan P. Wojciechowski, Ilias Koutsopetras, Phyllida Britton, Richard J. Spears, Ioanna A. Thanasi, Baihao Shao, Lisha Zhong, Dejan-Krešimir Bučar, Abil E. Aliev, Michael J. Porter, Molly M. Stevens, James R. Baker & Vijay Chudasama. (2023) Use of pyridazinediones for tuneable and reversible covalent cysteine modification applied to peptides, proteins and hydrogels. Chemical Science 14:47, pages 13743-13754.
Crossref
Crossref
Anjali Gupta & Joydev K. Laha. (2023) Growing Utilization of Radical Chemistry in the Synthesis of Pharmaceuticals. The Chemical Record 23:11.
Crossref
Crossref
John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak & Jennifer A. Woyach. (2023) Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood 142:8, pages 687-699.
Crossref
Crossref
Maissa Mhibik, Erika M. Gaglione, David Eik, John Herrick, Janet Le, Inhye E. Ahn, Christopher Chiu, Monica Wielgos-Bonvallet, Ida H. Hiemstra, Esther C. W. Breij, Jenny Chen, Edward B. Reilly, Pearlie K. Epling-Burnette, Edith Szafer-Glusman, Clare Sun & Adrian Wiestner. (2023) Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Advances 7:15, pages 4089-4101.
Crossref
Crossref
Gholamhossein Sodeifian, Loubna Nasri, Fariba Razmimanesh & Maryam Arbab Nooshabadi. (2023) Solubility of ibrutinib in supercritical carbon dioxide (Sc-CO2): Data correlation and thermodynamic analysis. The Journal of Chemical Thermodynamics 182, pages 107050.
Crossref
Crossref
Deyi Zhang, Hailey M. Harris, Jonathan Chen, Jen Judy, Gabriella James, Aileen Kelly, Joel McIntosh, Austin Tenn-McClellan, Eileen Ambing, Ying Siow Tan, Hao Lu, Stefan Gajewski, Matthew C. Clifton, Stephanie Yung, Daniel W. Robbins, Mehdi Pirooznia, Sigrid S. Skånland, Erika Gaglione, Maissa Mhibik, Chingiz Underbayev, Inhye E. Ahn, Clare Sun, Sarah E. M. Herman, Mark Noviski & Adrian Wiestner. (2023) NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Blood 141:13, pages 1584-1596.
Crossref
Crossref
Gulsah Congur. (2023) Electrochemical Biosensors for Monitoring of Drug-DNA Interactions. Current Topics in Medicinal Chemistry 23:4, pages 316-330.
Crossref
Crossref
Mengmeng Liu, Hui Gao, Yanxia He, Xueqing Sun & Lili Zhang. (2023) Upregulation of miR-101-3p Overcomes Ibrutinib Resistance by Targeting ABCC5 in Diffuse Large B-Cell Lymphoma (DLBCL). Journal of Hard Tissue Biology 32:1, pages 11-20.
Crossref
Crossref
Brad Hocking, Alan Armstrong & David J. Mann. 2023.
105
146
.
Lalitha Guruprasad, Priyanka Andola, Adrija Banerjee, Durgam Laxman & Gatta K.R.S. Naresh. 2023. Cheminformatics, QSAR and Machine Learning Applications for Novel Drug Development. Cheminformatics, QSAR and Machine Learning Applications for Novel Drug Development
205
237
.
Hongjin Zhai, Shuo Zhang, Maxwell Ampomah-Wireko, Huanhuan Wang, Yaquan Cao, Pu Yang, Yingxue Yang, Firas Obald Arhema Frejat, Lihong Wang, Bingbing Zhao, Changzhong Ren & Chunli Wu. (2022) Pyrazole: An Important Core in Many Marketed and Clinical Drugs. Russian Journal of Bioorganic Chemistry 48:6, pages 1175-1189.
Crossref
Crossref
Lydia Boike, Nathaniel J. Henning & Daniel K. Nomura. (2022) Advances in covalent drug discovery. Nature Reviews Drug Discovery 21:12, pages 881-898.
Crossref
Crossref
Yipeng Lin. (2022) Kinase inhibitor therapies for Chronic lymphocytic leukaemia (CLL): SYK, BTK and PI3K inhibitors. Highlights in Science, Engineering and Technology 19, pages 30-35.
Crossref
Crossref
Maria-Jesus Blanco, Kevin M. Gardinier & Mark N. Namchuk. (2022) Advancing New Chemical Modalities into Clinical Studies. ACS Medicinal Chemistry Letters 13:11, pages 1691-1698.
Crossref
Crossref
Simone A. Brysland, M. Gohar Maqbool, Dipti Talaulikar & Elizabeth E. Gardiner. (2022) Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes and Evaluation. Thrombosis and Haemostasis 122:11, pages 1843-1857.
Crossref
Crossref
Jennifer A. Woyach. (2022) Management of relapsed/refractory Chronic Lymphocytic Leukemia. American Journal of Hematology 97:S2.
Crossref
Crossref
Haoran Wang, Hao Guo, Jingyi Yang, Yanyan Liu, Xingchen Liu, Qing Zhang & Keshu Zhou. (2022) Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Selva Bilge, Burcu Dogan-Topal, Tugba Taskin Tok, Esen Bellur Atici, Ali Sınağ & Sibel A. Ozkan. (2022) Investigation of the interaction between anticancer drug ibrutinib and double-stranded DNA by electrochemical and molecular docking techniques. Microchemical Journal 180, pages 107622.
Crossref
Crossref
Liang Tu, Limei Gao, Qiang Wang, Zhixing Cao, Rong Huang, Yongsheng Zheng & Jikai Liu. (2022) Substrate-Switched Chemodivergent Pyrazole and Pyrazoline Synthesis: [3 + 2] Cycloaddition/Ring-Opening Rearrangement Reaction of Azadienes with Nitrile Imines. The Journal of Organic Chemistry 87:5, pages 3389-3401.
Crossref
Crossref
Adrian Minson, Constantine Tam, Michael Dickinson & John F. Seymour. (2022) Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. Cancers 14:5, pages 1276.
Crossref
Crossref
Sudarvizhi Thanigainathan, Sangamithra Ramalingan, Subramanianainar Meyyanathan & Basavan Babu. (2022) QbD Approach For Anti-Cancer Drugs - A Review. Current Pharmaceutical Analysis 18:3, pages 251-264.
Crossref
Crossref
Denisa-Corina Ciuculete, Raluca Alexandra Popescu, Georgeta Daniela Georgescu & Gheorghe-Andrei Dan. (2022) Evaluation of Ibrutinib Cardiotoxicity By Comparative Use of Speckle-Tracking Technique and Biomarkers. American Journal of Therapeutics 29:1, pages e50-e55.
Crossref
Crossref
Ali Khader, Rozan Bokhari, Reza Hakimelahi, Christopher Scheirey, Jalil Afnan, Marta Braschi-Amirfarzan & Richard Thomas. (2022) A radiologist’s guide to novel anticancer therapies in the era of precision medicine. European Journal of Radiology Open 9, pages 100406.
Crossref
Crossref
Simone A. Brysland, Muhammad Gohar Maqbool, Dipti Talaulikar & Elizabeth E. Gardiner. 2022.
Chen Guang Yu, Vimala Bondada, Hina Iqbal, Kate L. Moore, John C. Gensel, Subbarao Bondada & James W. Geddes. (2021) Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury. International Journal of Molecular Sciences 23:1, pages 355.
Crossref
Crossref
Limei Gao, Ruijie Shi, Yuting Tian, Xi Luo, Yongsheng Zheng & Qiang Wang. (2021) Synthesis of Pyrazoles through [3+2] Cyclization of Nitrile Imines with Cinnamaldehydes Followed by Air Oxidation. ChemistrySelect 6:45, pages 12838-12842.
Crossref
Crossref
Danling Gu, Hanning Tang, Jiazhu Wu, Jianyong Li & Yi Miao. (2021) Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Daniel Zaidman, Paul Gehrtz, Mihajlo Filep, Daren Fearon, Ronen Gabizon, Alice Douangamath, Jaime Prilusky, Shirly Duberstein, Galit Cohen, C. David Owen, Efrat Resnick, Claire Strain-Damerell, Petra Lukacik, Haim Barr, Martin A. Walsh, Frank von Delft & Nir London. (2021) An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. Cell Chemical Biology 28:12, pages 1795-1806.e5.
Crossref
Crossref
Michal Kriegelstein, Miloš Hroch & Aleš Marek. (2021)
Synthesis of [
13
C
6
]‐ibrutinib
. Journal of Labelled Compounds and Radiopharmaceuticals 64:13, pages 500-512.
Crossref
Crossref
Gerasimos Tsilimidos, Alice Horisberger, Camillo Ribi, Anne Cairoli & Gregoire Stalder. (2021) Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction. Clinical Lymphoma Myeloma and Leukemia 21:10, pages e745-e747.
Crossref
Crossref
Shiva Kumar Reddy Mukkamalla & Dhatri Malipeddi. (2021) Myeloma Bone Disease: A Comprehensive Review. International Journal of Molecular Sciences 22:12, pages 6208.
Crossref
Crossref
Hui Yu, Xing Wang, Jiao Li, Yingying Ye, Dedao Wang, Wei Fang, Lan Mi, Ning Ding, Xiaogan Wang, Yuqin Song & Jun Zhu. (2021) Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Molecular Therapy - Oncolytics 21, pages 158-170.
Crossref
Crossref
Justin K. Messex & Geou-Yarh Liou. (2021) Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option. Cancers 13:9, pages 2198.
Crossref
Crossref
Jiamin Zheng, Jun Wu, Xiao Ding, Hong C. Shen & Ge Zou. (2021) Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 38, pages 127862.
Crossref
Crossref
Jiazheng Li, Yan Huang, Yun Zhang, Jingjing Wen, Yanxin Chen, Lingyan Wang, Peifang Jiang & Jianda Hu. (2021) Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma. Medical Oncology 38:4.
Crossref
Crossref
Yuemin Bian, Jaden Jungho Jun, Jacob Cuyler & Xiang-Qun Xie. (2020) Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery. European Journal of Medicinal Chemistry 206, pages 112690.
Crossref
Crossref
Nagarjun Rangaraj, Sravanthi Reddy Pailla, Saurabh Shah, Shubham Prajapati & Sunitha Sampathi. (2020) QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. Drug Delivery and Translational Research 10:5, pages 1476-1494.
Crossref
Crossref
Kristina S. Lechner, Markus F. Neurath & Benno Weigmann. (2020) Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis. Journal of Molecular Medicine 98:10, pages 1385-1395.
Crossref
Crossref
Gerwin HulsDana A. ChituThomas PabstSaskia K. KleinGeorg Stussi, Laimonas GriskeviciusPeter J. M. ValkJacqueline Cloos, Arjan A. van de LoosdrechtDimitri BreemsDanielle van Lammeren-VenemaIsabelle van Zeventer, Rinske BoersmaMojca Jongen-LavrencicMartin FehrMels HoogendoornMarkus G. ManzMaaike SöhneRien van Marwijk KooyDries Deeren, Marjolein W. M. van der PoelMarie Cecile LegdeurLidwine TickYves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg & Gert J. Ossenkoppele. (2020) Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood Advances 4:18, pages 4267-4277.
Crossref
Crossref
Sukyo Jeong, Yoo-Kyoung Sohn, Yoonjoo Choi, Jinho Park & Hak-Sung Kim. (2020) A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton’s tyrosine kinase and its drug-resistant variants. Biochemical and Biophysical Research Communications 526:1, pages 8-13.
Crossref
Crossref
Mauro Angiolini. 2020. Structural Biology in Drug Discovery. Structural Biology in Drug Discovery
363
393
.
Michael Schaffer, Shalini Chaturvedi, Cuc Davis, Jan de Jong, Regina Aquino, Yasuhiro Oki, Nele Fourneau, Anas Younes & Sriram Balasubramanian. (2020) Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. Cancer Treatment and Research Communications 25, pages 100235.
Crossref
Crossref
Gasim DobieFahd A. Kuriri, Musab M. A. OmarFehaid AlanaziAli M. GazwaniChloe P. S. Tang, Daniel Man-yuen Sze, Sasanka M. Handunnetti, Constantine Tam & Denise E. Jackson. (2019) Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans. Blood Advances 3:24, pages 4298-4311.
Crossref
Crossref
Peng Wang, Yunxuan Luo, Songsong Zhu, Dengfu Lu & Yuefa Gong. (2019) Catalytic Azido‐Hydrazination of Alkenes Enabled by Visible Light: Mechanistic Studies and Synthetic Applications. Advanced Synthesis & Catalysis 361:24, pages 5565-5575.
Crossref
Crossref
Nagarjun Rangaraj, Sravanthi Reddy Pailla, Paramesh Chowta & Sunitha Sampathi. (2019) Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability. AAPS PharmSciTech 20:8.
Crossref
Crossref
Shujuan Huang, Jiajia Pan, Jing Jin, Chengying Li, Xia Li, Jiansong Huang, Xin Huang, Xiao Yan, Fengling Li, Mengxia Yu, Chao Hu, Jingrui Jin, Yu Xu, Qing Ling, Wenle Ye, Yungui Wang & Jie Jin. (2019) Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia. Cancer Letters 461, pages 132-143.
Crossref
Crossref
Yanyan Diao, Xiaoyu Fang, Peiran Song, Mengzhen Lai, Linjiang Tong, Yongjia Hao, Dou Dou, Yingqiang Liu, Jian Ding, Zhenjiang Zhao, Hua Xie & Honglin Li. (2019) Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton’s tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry 27:15, pages 3390-3395.
Crossref
Crossref
Xiaohan Hu, Bingbing Zhao, WenSheng Zou, Xuehui Yang & Pengwu Zheng. (2019) Synthesis of tert-butyl 4-bromo-4-formylpiperidine-1-carboxylate. IOP Conference Series: Earth and Environmental Science 252, pages 022085.
Crossref
Crossref
Eriong Lee‐Vergés, Bola S. Hanna, Haniyeh Yazdanparast, Vanina Rodríguez, Marta Leonor Rodríguez, Ariadna Giró, Anna Vidal‐Crespo, Laia Rosich, Virginia Amador, Marta Aymerich, Neus Villamor, Julio Delgado, Peter Lichter, Patricia Pérez‐Galán, Mònica López‐Guerra, Elías Campo, Martina Seiffert & Dolors Colomer. (2019) Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. International Journal of Cancer 144:11, pages 2762-2773.
Crossref
Crossref
G. Fraser, P. Cramer, F. Demirkan, R. Santucci Silva, S. Grosicki, A. Pristupa, A. Janssens, J. Mayer, N. L. Bartlett, M.-S. Dilhuydy, H. Pylypenko, J. Loscertales, A. Avigdor, S. Rule, D. Villa, O. Samoilova, P. Panagiotidis, A. Goy, M. A. Pavlovsky, C. Karlsson, M. Hallek, M. Mahler, M. Salman, S. Sun, C. Phelps, S. Balasubramanian, A. Howes & A. Chanan-Khan. (2018) Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia 33:4, pages 969-980.
Crossref
Crossref
Jan A. Burger, Mariela SivinaNitin JainEkaterina KimTapan KadiaZeev EstrovGraciela M. Nogueras-Gonzalez, Xuelin Huang, Jeffrey JorgensenJianling Li, Mei Cheng, Fong Clow, Maro OhanianMichael AndreeffThomas MathewPhilip ThompsonHagop KantarjianSusan O’Brien, William G. WierdaAlessandra FerrajoliMichael J. Keating. (2019) Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133:10, pages 1011-1019.
Crossref
Crossref
Hui Zhang & Longhui Qiu. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
109
124
.
Gerardo Ferrer & Emili Montserrat. (2018) Critical molecular pathways in CLL therapy. Molecular Medicine 24:1.
Crossref
Crossref
Tao Gong, Wei Jiang & Rongbin Zhou. (2018) Control of Inflammasome Activation by Phosphorylation. Trends in Biochemical Sciences 43:9, pages 685-699.
Crossref
Crossref
Jan A. Burger & Susan O’Brien. (2018) Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews Clinical Oncology 15:8, pages 510-527.
Crossref
Crossref
Chirag Patel, Margaret Mohnike, Michael C. Hilton & Andrew McNally. (2018) A Strategy to Aminate Pyridines, Diazines, and Pharmaceuticals via Heterocyclic Phosphonium Salts. Organic Letters 20:9, pages 2607-2610.
Crossref
Crossref
Itzel Bustos-Villalobos, Jennifer Williams Bergstrom, Nathan E. Haigh, Jesus I. Luna, Anupam Mitra, Alina I. Marusina, Alexander A. Merleev, Elizabeth A. Wang, Andrea Sukhov, Hawa Sultani, Ruiwu Liu, Gaurav Bhardwaj, Wenchang Guo, Hsing-Jien Kung, Kit S. Lam & Emanual Maverakis. (2017) ITK inhibition for the targeted treatment of CTCL. Journal of Dermatological Science 87:1, pages 88-91.
Crossref
Crossref
Varinder Kaur & Arjun Swami. (2017) Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Annals of Hematology 96:7, pages 1175-1184.
Crossref
Crossref
Sarah E.M. Herman, Arnau Montraveta, Carsten U. Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner & Jennifer A. Woyach. (2017) The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research 23:11, pages 2831-2841.
Crossref
Crossref
Steven E. Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, Jeffrey Jones, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd & Susan O'Brien. (2017) Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Cancer Research 23:5, pages 1149-1155.
Crossref
Crossref
Kami Maddocks, Paul M. Barr, Bruce D. Cheson, Richard F. Little, Lawrence Baizer, Brad S. Kahl, John P. Leonard, Nathan Fowler, Leo I. Gordon, Brian K. Link, Jonathan W. Friedberg & Stephen M. Ansell. (2016) Recommendations for Clinical Trial Development in Follicular Lymphoma. Journal of the National Cancer Institute 109:3, pages djw255.
Crossref
Crossref
Qingsong Yin, Mariela Sivina, Harlan Robins, Erik Yusko, Marissa Vignali, Susan O’Brien, Michael J. Keating, Alessandra Ferrajoli, Zeev Estrov, Nitin Jain, William G. Wierda & Jan A. Burger. (2017) Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. The Journal of Immunology 198:4, pages 1740-1747.
Crossref
Crossref
Jan A. Burger, Kelvin W. Li, Michael J. Keating, Mariela Sivina, Ahmed M. Amer, Naveen Garg, Alessandra Ferrajoli, Xuelin Huang, Hagop Kantarjian, William G. Wierda, Susan O’Brien, Marc K. Hellerstein, Scott M. Turner, Claire L. Emson, Shih-Shih Chen, Xiao-Jie Yan, Dominik Wodarz & Nicholas Chiorazzi. (2017) Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight 2:2.
Crossref
Crossref
Jingjing Wu, Mingzhi Zhang & Delong Liu. (2016) Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget 8:4, pages 7201-7207.
Crossref
Crossref
A Hamasy, Q Wang, K E M Blomberg, D K Mohammad, L Yu, M Vihinen, A Berglöf & C I E Smith. (2016) Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia 31:1, pages 177-185.
Crossref
Crossref
Sonja Sorensen, Mark Wildgust, Nishan Sengupta, Cristina Trambitas, Joris Diels, Suzy van Sanden, Yingxin Xu & Emily Dorman. (2017) Indirect Treatment Comparisons of Ibrutinib Versus Physician?s Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. Clinical Therapeutics 39:1, pages 178-189.e5.
Crossref
Crossref
Yingying Zuo & Zhengying Pan. 2018. Cancer II. Cancer II
75
104
.
Jun Chen, Taisei Kinoshita, Juthamas Sukbuntherng, Betty Y. Chang & Laurence Elias. (2016) Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth. Molecular Cancer Therapeutics 15:12, pages 2835-2844.
Crossref
Crossref
Zhenzhen Chen, Jinghuan Zhai, Xijian Liu, Shimin Mao, Lijuan Zhang, Sohrab Rohani & Jie Lu. (2016) Solubility measurement and correlation of the form A of ibrutinib in organic solvents from 278.15 to 323.15 K. The Journal of Chemical Thermodynamics 103, pages 342-348.
Crossref
Crossref
Denise E Jackson. (2016) The Importance of Bruton Tyrosine Kinase (BTK) and Targeted Therapies. Hematology & Transfusion International Journal 3:1.
Crossref
Crossref
Jorge J. Castillo, M. Lia Palomba, Ranjana Advani & Steven P. Treon. (2016) Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology 7:4, pages 179-186.
Crossref
Crossref
David L Tucker & Simon A Rule. (2016) Ibrutinib for mantle cell lymphoma. Future Oncology 12:4, pages 477-491.
Crossref
Crossref
Paula Cramer, Petra Langerbeins & Michael Hallek. (2016) Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia. The Cancer Journal 22:1, pages 62-66.
Crossref
Crossref
X Cui, L Zhang, A R Magli, R Catera, X-J Yan, D O Griffin, T L Rothstein, J Barrientos, J E Kolitz, S L Allen, K R Rai, N Chiorazzi & C C Chu. (2015) Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability. Leukemia 30:1, pages 74-85.
Crossref
Crossref
Urte Gayko, Mann Fung, Fong Clow, Steven Sun, Elizabeth Faust, Samiyeh Price, Danelle James, Margaret Doyle, Samina Bari & Sen Hong Zhuang. (2015) Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. Annals of the New York Academy of Sciences 1358:1, pages 82-94.
Crossref
Crossref
A. Berglöf, A. Hamasy, S. Meinke, M. Palma, A. Krstic, R. Månsson, E. Kimby, A. Österborg & C. I. E. Smith. (2015) Targets for Ibrutinib Beyond B Cell Malignancies. Scandinavian Journal of Immunology 82:3, pages 208-217.
Crossref
Crossref
J Eswaran, P Sinclair, O Heidenreich, J Irving, L J Russell, A Hall, D P Calado, C J Harrison & J Vormoor. (2015) The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia 29:8, pages 1623-1631.
Crossref
Crossref
Ignacio A. Rodriguez-Brenes & Dominik Wodarz. (2015) Preventing clonal evolutionary processes in cancer: Insights from mathematical models. Proceedings of the National Academy of Sciences 112:29, pages 8843-8850.
Crossref
Crossref
Michelle Furtado, Michael L. Wang, Brian Munneke, Jesse McGreivy, Darrin M. Beaupre & Simon Rule. (2015) Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. British Journal of Haematology 170:1, pages 131-134.
Crossref
Crossref
Antonino Carbone & Anas YounesPietro Bulian & Jan Burger. 2015. Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2). Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2)
56
71
.
Stuart A Rushworth, Genevra Pillinger, Amina Abdul-Aziz, Rachel Piddock, Manar S Shafat, Megan Y Murray, Lyubov Zaitseva, Matthew J Lawes, David J MacEwan & Kristian M Bowles. (2015) Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells. The Lancet Haematology 2:5, pages e204-e211.
Crossref
Crossref
Mingye Feng, James Y. Chen, Rachel Weissman-Tsukamoto, Jens-Peter Volkmer, Po Yi Ho, Kelly M. McKenna, Samuel CheshierMichael ZhangNan Guo, Phung Gip, Siddhartha S. MitraIrving L. Weissman. (2015) Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk. Proceedings of the National Academy of Sciences 112:7, pages 2145-2150.
Crossref
Crossref
Ye Yang, Jumei Shi, Zhimin Gu, Mohamed E. Salama, Satyabrata Das, Erik Wendlandt, Hongwei Xu, Junwei Huang, Yi Tao, Mu Hao, Reinaldo Franqui, Dana Levasseur, Siegfried Janz, Guido Tricot & Fenghuang Zhan. (2015) Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma. Cancer Research 75:3, pages 594-604.
Crossref
Crossref
Adrian Wiestner. (2014) BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology 2014:1, pages 125-134.
Crossref
Crossref
Natalia L. Komarova, Jan A. Burger & Dominik Wodarz. (2014) Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences 111:38, pages 13906-13911.
Crossref
Crossref
R. E. Walker, M. A. Lawson, C. H. Buckle, J. A. Snowden & A. D. Chantry. (2014) Myeloma bone disease: pathogenesis, current treatments and future targets. British Medical Bulletin 111:1, pages 117-138.
Crossref
Crossref
Jan A Burger, Michael J Keating, William G Wierda, Elena Hartmann, Julia Hoellenriegel, Nathalie Y Rosin, Iris de Weerdt, Ghayathri Jeyakumar, Alessandra Ferrajoli, Marylou Cardenas-Turanzas, Susan Lerner, Jeffrey L Jorgensen, Graciela M Nogueras-Gonz?lez, Gracy Zacharian, Xuelin Huang, Hagop Kantarjian, Naveen Garg, Andreas Rosenwald & Susan O'Brien. (2014) Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. The Lancet Oncology 15:10, pages 1090-1099.
Crossref
Crossref
Giorgia SimonettiMaria Teresa Sabrina BertilaccioPaolo Ghia & Ulf Klein. (2014) Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. Blood 124:7, pages 1010-1019.
Crossref
Crossref
Amin Aalipour & Ranjana H. Advani. (2014) Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therapeutic Advances in Hematology 5:4, pages 121-133.
Crossref
Crossref
Akintunde Akinleye, Muhammad Furqan & Oluwaseyi Adekunle. (2014) Ibrutinib and Indolent B-Cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia 14:4, pages 253-260.
Crossref
Crossref
Mariela Sivina, Robert J. Kreitman, Evgeny Arons, Farhad Ravandi & Jan A. Burger. (2014) The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. British Journal of Haematology 166:2, pages 177-188.
Crossref
Crossref
Dominik WodarzNaveen Garg, Natalia L. KomarovaOhad Benjamini, Michael J. Keating, William G. Wierda, Hagop Kantarjian, Danelle James, Susan O’Brien & Jan A. Burger. (2014) Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood 123:26, pages 4132-4135.
Crossref
Crossref
Sabine PonaderJan A. Burger. (2014) Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies. Journal of Clinical Oncology 32:17, pages 1830-1839.
Crossref
Crossref
Chih-Hang Anthony Tang, Sujeewa Ranatunga, Crystina L. Kriss, Christopher L. Cubitt, Jianguo Tao, Javier A. Pinilla-Ibarz, Juan R. Del Valle & Chih-Chi Andrew Hu. (2014) Inhibition of ER stress?associated IRE-1/XBP-1 pathway reduces leukemic cell survival. Journal of Clinical Investigation 124:6, pages 2585-2598.
Crossref
Crossref
Jan A. Burger. (2013) Bruton?s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials. Current Hematologic Malignancy Reports 9:1, pages 44-49.
Crossref
Crossref
Stuart A. RushworthMegan Y. MurrayLyubov ZaitsevaKristian M. Bowles & David J. MacEwan. (2014) Identification of Bruton’s tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 123:8, pages 1229-1238.
Crossref
Crossref
Nimish Shah & Simon Rule. (2014) Management perspective for mantle cell lymphoma. International Journal of Hematologic Oncology 3:1, pages 31-40.
Crossref
Crossref
Jan A. Burger & John G. Gribben. (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. Seminars in Cancer Biology 24, pages 71-81.
Crossref
Crossref
Aid? Tamara Staines Boone, Mar?a Guadalupe Torres Mart?nez, Gabriela L?pez Herrera, Julia O. de Leija Portilla, Sara Elva Espinosa Padilla, Francisco J. Espinosa Rosales & Sa?l Oswaldo Lugo Reyes. (2013) Gastric Adenocarcinoma in the Context of X-linked Agammaglobulinemia. Journal of Clinical Immunology 34:2, pages 134-137.
Crossref
Crossref
Wasif N. Khan, Jacqueline A. Wright, Eden Kleiman, Justin C. Boucher, Iris Castro & Emily S. Clark. (2013) B-lymphocyte tolerance and effector function in immunity and autoimmunity. Immunologic Research 57:1-3, pages 335-353.
Crossref
Crossref
Amin Aalipour & Ranjana H. Advani. (2013) Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. British Journal of Haematology 163:4, pages 436-443.
Crossref
Crossref
Michelle Vincendeau, Daniel Nagel, Andrea C Eitelhuber & Daniel Krappmann. (2013) MALT1 paracaspase: a unique protease involved in B-cell lymphomagenesis. International Journal of Hematologic Oncology 2:5, pages 409-417.
Crossref
Crossref
L. Vargas, A. Hamasy, B. F. Nore & C. I. E. Smith. (2013) Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases. Scandinavian Journal of Immunology 78:2, pages 130-139.
Crossref
Crossref
Robert C. Rickert. (2013) New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nature Reviews Immunology 13:8, pages 578-591.
Crossref
Crossref
Russell T. Naven, Sheila Kantesaria, Sashi Nadanaciva, Thomas Schroeter & Karen L. Leach. (2013) High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds. Toxicology Research 2:4, pages 235.
Crossref
Crossref